Month: May 2020

Cellectar Reports First Quarter 2020 Financial Results and Provides a Corporate Update

Written by Customer Service on May 7, 2020. Posted in Public Companies.

FLORHAM PARK, N.J., May 07, 2020 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the three months ended March 31, 2020 and provided a corporate update.First Quarter and Recent Corporate HighlightsAnnounced CLR 131 achieved primary efficacy endpoints from its Phase 2 CLOVER-1 study in median third line relapsed/refractory (r/r) and Non-Hodgkin’s lymphomas (NHL) and median sixth line r/r multiple myeloma (MM) and in the Phase 1 r/r MM dose escalation study at the 50mCi and 75mCi total body doses. The 75mCi total body dose demonstrated: Overall response rate (ORR) 42.8% in r/r MM33% ORR in triple class refractory r/r MM50% ORR in high risk r/r...

8i Enterprises Acquisition Corp. Announces Amendment to Agreement with Diginex Limited for Business Combination

Written by Customer Service on May 7, 2020. Posted in Public Companies.

NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) — 8i Enterprises Acquisition Corp. (NASDAQ: JFKKU, JFK, JFKKW, JFKKR) (“JFK” or the “Company”), a special purpose acquisition company, today announced that it has amended the Share Exchange Agreement (“Amendment”) with Diginex Limited (“Diginex” or the “Company”), a blockchain financial services and technology company, to extend the date by which it much complete its business combination to June 23, 2020 and to include new covenants and closing conditions of the parties.JFK has called a special shareholder meeting for June 15, 2020 to vote on the business combination along with the other proposals. All parties remain committed to the business combination, which if consummated, will result in Diginex becoming the first company listed on Nasdaq with a digital asset exchange.The Amendment, among...

Ársreikningur Hafnarfjarðarbæjar 2019

Written by Customer Service on May 7, 2020. Posted in Public Companies.

Rekstrarafgangur ársins 2019 fyrir A og B hluta bæjarsjóðs nam 1.236 milljónum króna en áætlun ársins með viðaukum gerði ráð fyrir 642 milljóna króna afgangi. Rekstrarniðurstaða ársins fyrir A hluta var jákvæð um 426 milljónir króna en áætlun gerði ráð fyrir 45 milljóna króna halla.Mismun á áætlun og niðurstöðu má einkum rekja til þess að gjaldfærsla lífeyrissjóðsskuldbindingar var um 392 milljónum krónum lægri en gert hafði verið ráð fyrir. Fjármagnsliðir voru einnig um 245 milljónum krónum lægri en áætlun gerði ráð fyrir vegna lægri verðbótaþáttar. Veltufé frá rekstri nam 3.396 milljónum króna eða 11,9% af heildartekjum.„Við höfum stigið varfærin og ábyrg skref í rekstri sveitarfélagsins. Niðurstöður ársreiknings 2019 eru í takti við áætlanir okkar og samræmist markmiðum um ábyrga fjármálastjórn og vel ígrundaðar ákvarðanir,“ segir...

Ársreikningur Hafnarfjarðarbæjar 2019

Written by Customer Service on May 7, 2020. Posted in Public Companies.

Press release Oncology Venture issues 1,952,475 new shares in connection with debt conversions

Written by Customer Service on May 7, 2020. Posted in Public Companies.

Hørsholm, Denmark, 7 May 2020 – Oncology Venture A/S (“OV” or the “Company”) today announces the issue of 1,952,475 new shares in connection with debt conversions.The Company has, based on a Board resolution from 6 May 2020, issued 1,952,475 new shares in connection with two debt conversions:Debt conversion of SEK 2,500,000 equivalent to 1,412,429 shares issued to Global Corporate Finance in connection with the Share Subscription Agreement announced on 6 May 2020, andDebt conversion of DKK 650,000 equivalent to 540,046 shares issued to a consultant for assistance in connection the establishment of 2X Oncology Inc. The new shares hold no special rights.The subscription will be made at a subscription rate of SEK 1.77 per share of nominal DKK 0.05.The share capital is after the conversion a total of DKK 6,630,927.70 divided into...

Atlantica Reports First Quarter 2020 Financial Results

Written by Customer Service on May 7, 2020. Posted in Dividend Reports And Estimates.

Net loss for the quarter attributable to the Company was $40.5 million, compared with a net loss of $9.0 million in the first quarter of 2019.Adjusted EBITDA including unconsolidated affiliates1 was $166.0 million, representing an 8.4% year-over-year decrease mostly due to foreign exchange differences and lower solar radiation in EMEA.Cash available for distribution (“CAFD”) increased by 5.4% year-over-year up to $47.6 million in the first quarter of 2020.Quarterly dividend of $0.41 per share declared by the Board of Directors.No material impact from Covid-19 situation as of today.Refinanced part of the solar assets in Spain with a Green Project Finance, unlocking approximately a $143 million “recap” expected to be used for new investments in renewable assets.Creation of a Renewable Energy Growth Platform with financial partners in Chile.May...

trivago N.V.’s First Quarter 2020 Earnings Release Scheduled for May 18, 2020; Webcast Scheduled for May 19, 2020

Written by Customer Service on May 7, 2020. Posted in Earnings Releases And Operating Results.

DÜSSELDORF, GERMANY – May 7, 2020 – trivago N.V. (NASDAQ: TRVG) announced today that it will release its financial results for the first quarter for the period ended March 31, 2020 on Monday, May 18, 2020 after market close. On the next day, Tuesday, May 19, 2020, trivago N.V.’s management will conduct a webcast beginning at 2:15 PM CEST / 8:15 AM EDT. These items will be available in the Investor Relations section of the company’s website at https://ir.trivago.com/. A replay of the call is expected to be available for at least three months.About trivago N.V.trivago N.V. (NASDAQ: TRVG) is a global hotel search platform. We are focused on reshaping the way travelers search for and compare hotels, while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers via our websites...

TearLab Corporation Confirms Merger Discussions

Written by Customer Service on May 7, 2020. Posted in Mergers And Acquisitions.

ESCONDIDO, Calif., May 07, 2020 (GLOBE NEWSWIRE) — In light of recent market rumors, TearLab Corporation (OTCQB: TEAR) (“TearLab”) today confirmed that TearLab is engaged in advanced discussions regarding a potential business combination whereby TearLab will be acquired at a price per share equal to $0.0586. Any transaction would be subject to the approval of TearLab’s board of directors and stockholders, as well as other customary conditions contained in a definitive agreement.TearLab cautioned that no agreement has been reached. TearLab also noted that there cannot be any assurance that an agreement will be reached or, if an agreement is reached, that a transaction will be completed. Accordingly, prior to making investment decisions, investors should take into consideration all publicly available information about TearLab, including...

Esperion to Participate in Fireside Chat at the BofA Securities 2020 Healthcare Conference

Written by Customer Service on May 7, 2020. Posted in Public Companies.

ANN ARBOR, Mich., May 07, 2020 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the BofA Securities 2020 Healthcare Conference on Tuesday, May 12, 2020, at 9:00 a.m. Eastern Time.A live audio webcast of this event can be accessed on the investor relations section of the Esperion website at www.esperion.com/investors-media/events-presentations/. Replay of the webcast will be archived on the Company’s website for 90 days following the event.Esperion TherapeuticsThrough scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make a substantial impact on reducing...

electroCore to Announce First Quarter Ended March 31, 2020 Financial Results on Thursday, May 14

Written by Customer Service on May 7, 2020. Posted in Public Companies.

BASKING RIDGE, N.J., May 07, 2020 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the first quarter ended March 31, 2020 after the close of the market on Thursday, May 14, 2020. Management will host a conference call and webcast at 4:30pm Eastern Time to discuss the financial results and answer questions.About electroCore, Inc.electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology and rheumatology. The company’s initial targets are the preventative treatment of cluster headache and acute treatment of migraine and episodic cluster headache.For...

Month: May 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals